Opko Health, Inc. OPK
We take great care to ensure that the data presented and summarized in this overview for OPKO HEALTH, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding OPK
View all-
Rubric Capital Management LP New York, NY48.7MShares$77.4 Million2.02% of portfolio
-
Black Rock Inc. New York, NY29.2MShares$46.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA29.2MShares$46.5 Million0.0% of portfolio
-
State Street Corp Boston, MA8.72MShares$13.9 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA8.37MShares$13.3 Million0.0% of portfolio
-
Invesco Ltd. Atlanta, GA6.03MShares$9.59 Million0.0% of portfolio
-
Charles Schwab Investment Management Inc San Francisco, CA4.21MShares$6.7 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL3.53MShares$5.62 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY2.74MShares$4.36 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.5MShares$3.98 Million0.0% of portfolio
Latest Institutional Activity in OPK
Top Purchases
Top Sells
About OPK
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins. The company also offers specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. In addition, it operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.
Insider Transactions at OPK
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Dec 11
2024
|
Phillip Md Et Al Frost CEO & Chairman |
BUY
Open market or private purchase
|
Indirect |
500,000
+0.23%
|
$500,000
$1.56 P/Share
|
Nov 29
2024
|
Phillip Md Et Al Frost CEO & Chairman |
BUY
Open market or private purchase
|
Indirect |
199,072
+0.09%
|
$199,072
$1.53 P/Share
|
Nov 22
2024
|
Phillip Md Et Al Frost CEO & Chairman |
BUY
Open market or private purchase
|
Indirect |
100,000
+0.05%
|
$100,000
$1.59 P/Share
|
Nov 14
2024
|
Phillip Md Et Al Frost CEO & Chairman |
BUY
Open market or private purchase
|
Indirect |
100,000
+0.05%
|
$100,000
$1.62 P/Share
|
Nov 08
2024
|
Phillip Md Et Al Frost CEO & Chairman |
BUY
Open market or private purchase
|
Indirect |
280,183
+0.13%
|
$280,183
$1.5 P/Share
|
Jul 24
2024
|
Phillip Md Et Al Frost CEO & Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
500,000
+12.29%
|
-
|
Jul 24
2024
|
Adam Logal Sr. Vice President, CFO |
BUY
Grant, award, or other acquisition
|
Direct |
437,500
+41.5%
|
-
|
Jul 24
2024
|
Jane Ph D Hsiao Vice Chairman & CTO |
BUY
Grant, award, or other acquisition
|
Direct |
500,000
+1.72%
|
-
|
Jul 24
2024
|
Steven D Rubin Executive VP-Administration |
BUY
Grant, award, or other acquisition
|
Direct |
437,500
+6.19%
|
-
|
Jul 24
2024
|
Gary J. Nabel Chief Innovation Officer |
BUY
Grant, award, or other acquisition
|
Direct |
437,500
+38.44%
|
-
|
Jul 24
2024
|
Elias A. Zerhouni Vice Chairman and President |
BUY
Grant, award, or other acquisition
|
Direct |
500,000
+45.89%
|
-
|
May 23
2024
|
Phillip Md Et Al Frost CEO & Chairman |
BUY
Open market or private purchase
|
Indirect |
100,000
+0.02%
|
$100,000
$1.27 P/Share
|
May 17
2024
|
Phillip Md Et Al Frost CEO & Chairman |
BUY
Open market or private purchase
|
Indirect |
163,997
+0.08%
|
$163,997
$1.29 P/Share
|
Mar 18
2024
|
Phillip Md Et Al Frost CEO & Chairman |
BUY
Open market or private purchase
|
Indirect |
500,000
+0.24%
|
$0
$0.87 P/Share
|
Mar 14
2024
|
Phillip Md Et Al Frost CEO & Chairman |
BUY
Open market or private purchase
|
Indirect |
500,000
+0.24%
|
$0
$0.89 P/Share
|
Mar 13
2024
|
Phillip Md Et Al Frost CEO & Chairman |
BUY
Open market or private purchase
|
Indirect |
500,000
+0.24%
|
$0
$0.93 P/Share
|
Mar 12
2024
|
Phillip Md Et Al Frost CEO & Chairman |
BUY
Open market or private purchase
|
Indirect |
600,000
+0.29%
|
$0
$0.93 P/Share
|
Feb 28
2024
|
Phillip Md Et Al Frost CEO & Chairman |
BUY
Open market or private purchase
|
Indirect |
500,000
+0.24%
|
$0
$0.99 P/Share
|
Feb 21
2024
|
Phillip Md Et Al Frost CEO & Chairman |
BUY
Open market or private purchase
|
Indirect |
1,000,000
+0.48%
|
$0
$0.99 P/Share
|
Feb 07
2024
|
Phillip Md Et Al Frost CEO & Chairman |
BUY
Open market or private purchase
|
Indirect |
1,500,000
+0.72%
|
$0
$0.98 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 2.81M shares |
---|---|
Open market or private purchase | 11.6M shares |